Hgk Asset Management Inc Pacira Bio Sciences, Inc. Transaction History

Hgk Asset Management Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 18, 2022	SELL	$51.24 - $58.89 $296,987 - $341,326	-5,796 Reduced 57.39%	4,304 $229,000
Q2 2022 Jul 29, 2022	SELL	$51.49 - $81.64 $6,796 - $10,776	-132 Reduced 1.29%	10,100 $589,000
Q1 2022 May 04, 2022	BUY	$60.03 - $76.49 $27,853 - $35,491	464 Added 4.75%	10,232 $781,000
Q4 2021 Feb 01, 2022	SELL	$47.97 - $62.21 $294,008 - $381,285	-6,129 Reduced 38.55%	9,768 $588,000
Q2 2021 Jul 30, 2021	BUY	$59.18 - $69.99 $208,195 - $246,224	3,518 Added 28.42%	15,897 $965,000
Q1 2021 Apr 15, 2021	BUY	$59.31 - $78.82 $26,808 - $35,626	452 Added 3.79%	12,379 $868,000
Q4 2020 Jan 08, 2021	BUY	$50.47 - $66.26 $284,499 - $373,507	5,637 Added 89.62%	11,927 $714,000
Q3 2020 Nov 05, 2020	BUY	$51.97 - $63.0 $326,891 - $396,270	6,290 New	6,290 $378,000

263

50.4M

429K

391K

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $892M
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

Get notified when there are updates to the investment portfolio of Hgk Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Hgk Asset Management Inc with notifications on news.